In the Boardroom
Refine search
Biotechnology
After the close of stock markets on Friday, the Wall street Journal (WSJ) reported (here) that Director of the Center for Biologics Evaluation and Research (CBER), Dr Vinay Prasad, will leave the agency in April. 7 March 2026
Pharmaceutical
Seattle-based Nautilus Biotechnology, a specialist in single-molecule proteome analysis, has announced the appointment of Amber Faust as vice president of sales. 6 March 2026
Pharmaceutical
Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization following the divestment of opioid dependence treatment Zubsolv (buprenorphine/naloxone). 6 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Pharmaceutical
US clinical-stage biotech Latigo Biotherapeutics has appointed Neha Krishnamohan as chief financial officer and chief business officer, adding a finance executive with experience across biotech capital markets and corporate strategy as the company advances its non-opioid pain pipeline. 4 March 2026
Biotechnology
UK-based 4basebio, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer. 3 March 2026
Pharmaceutical
Scotland-based contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services, a specialist in the GMP sterile fill-finish manufacturing of injectable drug products, has announced the appointment of Joanne Anderson as its chief commercial officer (CCO). 3 March 2026
Biotechnology
Danish vaccine maker Bavarian Nordic announced today, that the board of directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. 3 March 2026
Biotechnology
California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations. In this role, Ms Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors. 3 March 2026
Generics
Hikma Pharmaceuticals today reported its audited results for the year ended December 31, 2025. The company’s shares were down almost 15% at 1,406 pence by early afternoon. 26 February 2026
Biotechnology
Douglas Ingram has told Sarepta Therapeutics of his decision to retire as chief executive of the US genetic medicines company by the end of 2026 or upon the appointment of his replacement. 26 February 2026
Pharmaceutical
Ireland headquartered Alkermes (Nasdaq: ALKS) has announced that Richard Pops will retire from his role as chief executive (CEO), effective July 31, 2026. 26 February 2026
Pharmaceutical
UK biotech N4 Pharma has appointed David Solomon as chief executive and unveiled plans to rename itself Thalia Therapeutics, marking a decisive shift into proprietary RNA medicines focused initially on cardiovascular disease. 24 February 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello has announced that Henriette Mersebach will step down imminently as executive vice president, research and development, and as a member of the board. 20 February 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo has appointed Dr John Tsai as its new global head of R&D, to succeed Dr Ken Takeshita, who is stepping down from his post effective April 1, 2026. 20 February 2026
Biotechnology
Spain-based Biofabri, the human vaccines subsidiary of the biopharmaceutical group Zendal, has added Rolando Pajón Feyt, an international expert in immunotherapy and vaccine development, to its management team to strengthen the final phase of clinical development of its tuberculosis vaccine candidate, MTBVAC. 17 February 2026
Biotechnology
French clinical-stage biotech Sensorion, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Nawal Ouzren, Sensorion’s chief executive (CEO) and a director of the company, is stepping down from both posts due to a personal matter incompatible with serving as CEO. 17 February 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma today announced the appointment of three senior leaders to strengthen its late-stage development capabilities and preparation for commercial readiness. 16 February 2026
Biotechnology
Juvenescence, an Abu Dhabi, UAE-based clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan, today announced the appointment of Eileen Jennings-Brown as chief technology officer. 16 February 2026
Biotechnology
After the close of stock markets on Friday, the Wall street Journal (WSJ) reported (here) that Director of the Center for Biologics Evaluation and Research (CBER), Dr Vinay Prasad, will leave the agency in April. 7 March 2026
Pharmaceutical
Seattle-based Nautilus Biotechnology, a specialist in single-molecule proteome analysis, has announced the appointment of Amber Faust as vice president of sales. 6 March 2026
Pharmaceutical
Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization following the divestment of opioid dependence treatment Zubsolv (buprenorphine/naloxone). 6 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Pharmaceutical
US clinical-stage biotech Latigo Biotherapeutics has appointed Neha Krishnamohan as chief financial officer and chief business officer, adding a finance executive with experience across biotech capital markets and corporate strategy as the company advances its non-opioid pain pipeline. 4 March 2026
Biotechnology
UK-based 4basebio, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer. 3 March 2026
Pharmaceutical
Scotland-based contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services, a specialist in the GMP sterile fill-finish manufacturing of injectable drug products, has announced the appointment of Joanne Anderson as its chief commercial officer (CCO). 3 March 2026
Biotechnology
Danish vaccine maker Bavarian Nordic announced today, that the board of directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. 3 March 2026
Biotechnology
California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations. In this role, Ms Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors. 3 March 2026
Generics
Hikma Pharmaceuticals today reported its audited results for the year ended December 31, 2025. The company’s shares were down almost 15% at 1,406 pence by early afternoon. 26 February 2026
Biotechnology
Douglas Ingram has told Sarepta Therapeutics of his decision to retire as chief executive of the US genetic medicines company by the end of 2026 or upon the appointment of his replacement. 26 February 2026
Pharmaceutical
Ireland headquartered Alkermes (Nasdaq: ALKS) has announced that Richard Pops will retire from his role as chief executive (CEO), effective July 31, 2026. 26 February 2026
Pharmaceutical
UK biotech N4 Pharma has appointed David Solomon as chief executive and unveiled plans to rename itself Thalia Therapeutics, marking a decisive shift into proprietary RNA medicines focused initially on cardiovascular disease. 24 February 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello has announced that Henriette Mersebach will step down imminently as executive vice president, research and development, and as a member of the board. 20 February 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo has appointed Dr John Tsai as its new global head of R&D, to succeed Dr Ken Takeshita, who is stepping down from his post effective April 1, 2026. 20 February 2026
Biotechnology
Spain-based Biofabri, the human vaccines subsidiary of the biopharmaceutical group Zendal, has added Rolando Pajón Feyt, an international expert in immunotherapy and vaccine development, to its management team to strengthen the final phase of clinical development of its tuberculosis vaccine candidate, MTBVAC. 17 February 2026
Biotechnology
French clinical-stage biotech Sensorion, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Nawal Ouzren, Sensorion’s chief executive (CEO) and a director of the company, is stepping down from both posts due to a personal matter incompatible with serving as CEO. 17 February 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma today announced the appointment of three senior leaders to strengthen its late-stage development capabilities and preparation for commercial readiness. 16 February 2026
Biotechnology
Juvenescence, an Abu Dhabi, UAE-based clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan, today announced the appointment of Eileen Jennings-Brown as chief technology officer. 16 February 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A clinical-stage biopharmaceutical company focused on advancing selected therapeutic assets through mid-stage clinical development. Medicus Pharma’s operating model centers on generating Phase II proof-of-concept data and partnering or licensing programs to larger pharmaceutical companies for late-stage development and commercialization.
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze